Novartis AG
NVS
$125.50
$0.490.39%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.24% | -15.59% | -15.65% | -19.59% | 124.64% |
| Total Depreciation and Amortization | 94.89% | 75.70% | 62.14% | 47.56% | -63.39% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 418.07% | 584.76% | 396.33% | 519.40% | -131.38% |
| Change in Net Operating Assets | 54.99% | 42.03% | 36.33% | 4.73% | -122.17% |
| Cash from Operations | 31.93% | 37.99% | 38.01% | 21.86% | -0.31% |
| Capital Expenditure | -23.31% | -26.86% | -24.49% | -28.87% | -26.46% |
| Sale of Property, Plant, and Equipment | -70.94% | -76.68% | -56.82% | -63.71% | 16.00% |
| Cash Acquisitions | 41.94% | 69.25% | 0.40% | -12.83% | -1.15% |
| Divestitures | 244.07% | 343.75% | 740.91% | 3,466.67% | -- |
| Other Investing Activities | -50.38% | -1,402.34% | -11.48% | -123.27% | -115.37% |
| Cash from Investing | 6.96% | 34.14% | -6.08% | -234.26% | -205.96% |
| Total Debt Issued | -82.11% | 5.07% | 310.19% | 411.84% | 4,403.55% |
| Total Debt Repaid | 26.57% | 39.18% | -30.14% | -1.09% | 6.54% |
| Issuance of Common Stock | -23.33% | 4.00% | -- | -81.13% | -81.13% |
| Repurchase of Common Stock | -53.76% | -97.39% | -43.40% | 4.50% | 32.73% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.54% | -2.54% | -48.84% | -5.09% | -5.09% |
| Other Financing Activities | -645.00% | -110.37% | -104.78% | -105.95% | -101.18% |
| Cash from Financing | -108.98% | -74.83% | -47.71% | 17.76% | 47.05% |
| Foreign Exchange rate Adjustments | 28.41% | 355.42% | 106.02% | -398.00% | 117.28% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | 200.00% |
| Net Change in Cash | -436.63% | 58.18% | 5.06% | -132.91% | -67.27% |